Good morning. I'm Nello Mainolfi, President and CEO of Kymera Therapeutics, and I will act as the chairperson of this meeting. I'm pleased to welcome you to the Kymera Therapeutics 2026 Annual Meeting of Shareholders. Before I call the meeting to order, I would like to introduce you to the members of our board and executive team who are here with us today. The other members of the board with us today are Mr. Jeff Albers, Dr. Felix Baker, Dr. Bruce Booth, Dr. Pamela Esposito, Dr. Gorjan Hrustanovic, Dr. John Maraganore, Ms. Elena Ridloff, Dr. Victor Sandor. The other executive officers of the corporation with us today are Mr. Brian Adams, our Chief Legal Officer and Corporate Secretary, Dr. Jared Gollob, our Chief Medical Officer, Mr. Noah Goodman, our Chief Business Officer, and Mr. Bruce Jacobs, our Chief Financial Officer.
I would like to introduce Brendan McCrory of Ernst & Young, the corporation's independent registered public accounting firm. The meeting will now officially come to order. We propose to proceed with the formal business of the meeting as set forth in the corporation's 2026 Notice of Annual Meeting and Proxy Statement. The meeting will be conducted, and questions will be considered in the manner outlined in the rules of conduct and procedures available on the virtual meeting website. Will the secretary please report at this time with respect to the mailing of the notice of the meeting and the shareholders list?
I have at this meeting a complete list of the shareholders of record of the corporation at the close of business on April 27, 2026, the record date for this meeting, which is and will be available for examination by any shareholder on the virtual meeting website throughout this meeting. I also have with me an affidavit certifying that commencing on April 29, 2026, a notice of Internet availability of proxy materials was deposited in the United States Mail to all shareholders of record as of April 27, 2026. The notice provided that shareholders could access and review the corporation's proxy materials, including the proxy card, proxy statement, notice of meeting, and 2025 annual report, or alternatively request a print copy of the proxy materials.
At this time, I'd like to introduce Lew Larson, who has been appointed to act as independent inspector of elections at this meeting. Mr. Larson has taken and subscribed the customary oath of office to execute his duties with strict impartiality, which will be filed with the records of the meeting. His function is to decide upon the qualifications of voters, accept their votes, and when balloting on all matters is completed, to tally the final votes. Will the secretary please report at this time with respect to the existence of a quorum?
I've been informed by the Inspector of Elections that proxies have been received for 79,100,162 of the 82,257,588 shares of common stock outstanding on the record date, which represents approximately 96.16% of the total number of shares entitled to vote at this meeting. This constitutes a quorum for the meeting today. We may now carry out the official business of the meeting.
We will now proceed with the formal business of the meeting. The following proposals are to be considered by our shareholders at this meeting. Proposal one is the election of Bruce Booth, Nello Mainolfi, John Maraganore, and Elena Ridloff as Class III directors to serve on the board of directors until 2029 annual meetings of shareholders, and until his or her successors are duly elected and qualified, or until his or her respective earlier death, resignation, or removal. The board recommends voting for the Class III director nominees. Proposal two is to approve, on a non-binding advisory basis, the compensation of the corporation's named executive officers as disclosed in the proxy statement. The board recommends a vote for the approval on a non-binding advisory basis of the compensation of the corporation's named executive officers as disclosed in the proxy statement.
Proposal three is to ratify the appointment of Ernst & Young as the corporation's independent registered public accounting firm for the fiscal year ending in December 31st, 2026. The board recommends a vote for the ratification of the appointment of Ernst & Young as the corporation's independent registered public accounting firm for the fiscal year ending December 31st, 2026. That was the final proposal for today's meeting. Mr. Brian Adams, Mr. Bruce Jacobs, and I were designated as proxies by certain shareholders. Such shares represented by proxy will be voted in accordance with the instructions given. If no instructions were given, such shares will be voted in accordance with the board's recommendation. The secretary will now describe the voting procedures.
The time is now 8:35 A.M. Eastern Time on Wednesday, June 24th, 2026. The polls are now open for voting on each of the proposals described by the chairperson. Voting is by proxy and virtual written ballot. You do not need to vote again if you have already voted your proxy by telephone, by mail, or by Internet. Will Mr. Jacobs please advise if we have any questions?
We have no questions.
The time is now 8:36 A.M. Eastern Time, and the polls are now closed for voting on each matter presented.
May we have the results of the voting?
The report of the Inspector of Elections covering the proposals presented at this meeting is as follows: The proposal to elect all directors is carried. The proposal to approve, on a non-binding advisory basis, the compensation of the corporation's named executive officers as disclosed in the proxy statement is carried. The proposal to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the corporation for the year ending December 31, 2026 is carried.
There being no other business to properly come before this meeting, this meeting is now adjourned. Thank you for attending the corporation's 2026 Annual Meeting of Shareholders.
This now concludes the meeting. Thank you for joining, and have a pleasant day.